文献速递乳腺癌

浸润性小叶乳腺癌患者的临床挑战与拟议解决方案

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.
PubMed 文献 · Ann Oncol · 2025-07-21

欧洲和美国浸润性小叶癌(ILC)专家总结了ILC在组织病理诊断、影像学和治疗方面的近期进展、进行中的努力及剩余挑战。近期已制定指南推动ILC病理诊断更统一和标准化,但组织学与生物学亚分类的细化、人工智能病理诊断指征的确定、影像新模态(对比增强乳腺摄影、新型PET示踪剂、扩散加权MRI)的评估、临床试验疗效评估替代RECIST v1.1标准的需求、液体活检检测疾病进展的专门研究,以及针对ILC的新型乳腺癌治疗疗效和靶向ILC特异性或富集靶点药物的评估,均需进一步研究。尽管ILC研究已取得很大进展,仍有许多挑战需要临床进一步研究以优化治疗和结局。

要点

  • 近期努力已促成指南,使ILC病理诊断更统一和标准化。
  • 标准影像工具对ILC筛查和分期欠佳,对比增强乳腺摄影、新型PET示踪剂和扩散加权MRI正在研究中。
  • RECIST v1.1对转移性ILC并非普遍适用,临床试验疗效评估需替代标准。

核心结论

  • 尽管ILC研究已取得很大进展,仍有许多挑战需要临床进一步研究以优化治疗和结局。

研究设计与样本

  • 欧洲和美国ILC专家总结ILC组织病理诊断、影像学和治疗的近期进展、进行中的努力及剩余挑战。

主要发现

  • 近期努力已促成指南,使ILC病理诊断更统一和标准化。
  • 未来需细化组织学与生物学亚分类并确定人工智能用于病理诊断的指征。
  • 标准影像工具对ILC筛查和局部及全身分期欠佳,对比增强乳腺摄影、新型PET示踪剂和扩散加权MRI正在研究中。
  • RECIST v1.1对转移性ILC并非普遍适用,临床试验疗效评估需替代标准。
  • 液体活检检测疾病进展需专门研究;新型乳腺癌治疗疗效需专门针对ILC评估,靶向ILC特异性或富集靶点药物的评估 warranted。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive lobular carcinoma (ILC) is the second most common type of breast cancer and is increasingly recognized as a separate entity from invasive breast cancer of no-special type. Here, we present the current standings and challenges of clinical ILC research and discuss possible solutions to address these challenges. DESIGN: European and United States experts on ILC have summarized the recent developments, ongoing endeavors and remaining challenges concerning the histopathological diagnosis, imaging and treatment of ILC. RESULTS: Recent endeavors have led to guidelines for a more uniform and standardized pathological diagnosis of ILC. Future efforts are needed to refine the histological and biological subclassification and determine the indications for use of artificial intelligence for pathological diagnosis. Since standard-of-care imaging tools are suboptimal for ILC screening and local and systemic staging, new modalities such as contrast-enhanced mammography, novel positron emission tomography tracers and diffusion-weighted magnetic resonance imaging are under investigation. An alternative to the currently used RECIST v1.1 criteria is needed for clinical trial response assessment, as it is not uniformly applicable for patients with metastatic ILC. The use of liquid biopsies for detecting disease progression needs dedicated research. Regarding treatment, the efficacy of novel breast cancer therapies needs to be examined specifically for ILC, and evaluation of drugs targeting ILC-specific or enriched targets is warranted. CONCLUSIONS: While great progress has been made in ILC research, many challenges remain and require further investigation in the clinic to optimize treatment and outcomes for those diagnosed with this common tumor type.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Van Baelen K, Sawyer E, Van Cauwenberge J, et al. Clinical challenges and proposed solutions for patients with invasive lobular breast cancer. Ann Oncol. 2025. PMID: 40701440. doi:10.1016/j.annonc.2025.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。